Highlights

  • FY26 group revenue increased 2.1% to $1.37 billion.
  • Underlying EBITDA increased 8.1% to $258.6 million.
  • Underlying EBIT grew 76.6% to $30.2 million.
  • Pathology and Agilex Biolabs recorded different rates of revenue growth.

Healius Limited (ASX:HLS) operates pathology and associated diagnostic laboratory services in Australia, together with specialist laboratory activities. The FY26 results released in August reported revenue growth and an increase in underlying operating earnings as the company continued work on service efficiency and cost management.

Pathology and Laboratory Services

Pathology services involve sample collection, processing and clinical testing. Laboratory capacity, collection networks and processing costs are important parts of the company’s operations. The group’s specialist Agilex Biolabs activities have a different service profile from mainstream pathology, so segment performance needs to be distinguished from consolidated results.

Healius’s FY26 reporting places particular emphasis on the relationship between revenue, operating costs and margins. The company has been pursuing improvements in productivity and its network. Such activities can alter the cost of delivering tests even when growth in the number of services or revenue is relatively modest.

Annual Results and Segment Contributions

For FY26, (ASX:HLS) reported group revenue of $1.37 billion, up 2.1% YoY. Underlying EBITDA increased 8.1% to $258.6 million and underlying EBIT rose 76.6% to $30.2 million. The figures distinguish operating earnings before depreciation and amortisation from earnings after those expenses.

An increase in underlying EBIT that exceeds the rate of revenue growth can reflect changes in operating costs, depreciation-related effects or the mix of services. However, the company’s reported measures should not be treated as equivalent to statutory net profit. Underlying figures exclude certain items according to the company’s reporting definitions.

Healius said pathology revenue increased 1.8% during FY26, while Agilex Biolabs revenue rose 14.1%. The different growth rates show that the group’s component activities did not change at the same pace. It is therefore useful to consider both the overall total and the particular contributions disclosed for these business lines.

In its February 2026 half-year report, (ASX:HLS) had recorded group revenue of $688.1 million and underlying EBITDA of $122.2 million for the first half. These figures covered only six months and should not be directly substituted for the full-year results. Together the interim and annual releases provide the chronology of the company’s 2026 reporting.

Productivity and Financial Priorities

Management described improved second-half pathology margins and continued attention to costs in its FY26 materials. The company identified network optimisation and technology-enabled productivity as operational priorities. These themes relate to how laboratory and collection services are organised rather than to a change in the basic diagnostic role of the business.

Healius also discussed an FY27 underlying EBIT expectation of $39.7 million in its August 2026 release. This is prospective management guidance, not a completed financial outcome. It must be distinguished from the $30.2 million underlying EBIT reported for FY26, which describes the financial year already ended.

For (ASX:HLS), the difference between revenue growth and operating earnings growth is a key feature of FY26. The reporting indicates improved underlying profitability while the group continued to address costs across its operations. No implication about future share-price direction follows directly from those accounting results.

The company held its annual general meeting in October 2026. Its published results and subsequent corporate communications provide separate reference points for assessing completed performance and management priorities. Any changes in future margins depend on actual laboratory operating conditions and will be reflected in later company disclosures.

Key Insights

Healius reported higher FY26 revenue and underlying earnings, with pathology and specialist laboratory operations making different contributions. For (ASX:HLS), the distinction between completed FY26 figures, management’s FY27 expectations and the underlying versus statutory accounting measures is important.